Endothelin receptor antagonists reduce blood pressure and proteinuria in chronic kidney disease and cause regression of renal injury in animal models.
Do endothelin receptor antagonists improve renal outcomes in patients with kidney disease?
Endothelin receptor antagonists show therapeutic potential for kidney disease by reducing blood pressure and proteinuria, though clinical evidence is currently limited mostly to diabetic nephropathy.
Our growing understanding of the role of the endothelin (ET) system in renal physiology and pathophysiology is from emerging studies of renal disease in animal models and humans. ET receptor antagonists reduce blood pressure and proteinuria in chronic kidney disease and cause regression of renal injury in animals. However, the therapeutic potential of ET receptor antagonism has not been fully explored and clinical studies have been largely limited to patients with diabetic nephropathy. There remains a need for more work in nondiabetic chronic kidney disease, end-stage renal disease (patients requiring maintenance dialysis and those with a functioning kidney transplant), ischemia reperfusion injury, and sickle cell disease. The current review summarizes the most recent advances in both preclinical and clinical studies of ET receptor antagonists in the field of kidney disease.
Czopek et al. (Thu,) conducted a review in Kidney disease. Endothelin receptor antagonists was evaluated. Endothelin receptor antagonists reduce blood pressure and proteinuria in chronic kidney disease and cause regression of renal injury in animal models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: